DETAILED ACTION
Applicant’s amendment and remarks filed August 24, 2026 are acknowledged. Claims 5, 6 and 8 are under examination.
Any prior objection or rejection that is not repeated or addressed below is withdrawn in view of Applicant’s amendment.
Priority
Acknowledgment is made of applicant's claim for foreign priority based on applications CN2022100273107, CN202111212401, and CN2021106138706, all filed in China on June 2, 2021. It is noted, however, that Applicant has not filed a certified copy of CN2022100273107 or CN202111212401 as required by 37 CFR 1.55.
In the reply filed August 24, 2026, Applicant indicates that they have submitted certified copies of both applications with WIPO DAS. In response, the Office had attempted and failed to retrieve the documents three times (10/19/2023, 8/21/2024, and 8/28/2024) before Applicant’s most recent submission to WIPO DAS. Therefore, Applicant must submit a certified copy to the USPTO by mail. Anything further or additional information will need to be directed to Application Assistance Unit on how the mailed certified copy of the foreign priority document needs to be sent to the USPTO. The toll-free number for the Application Assistance Unit is 888-786-0101. Their email address is HelpAAU@uspto.gov. Hours are M-F (except federal holidays) from 8:30 a.m. to 5 p.m. ET.
Specification
The disclosure is objected to because of the following informalities:
The use of the term “Eppendorf”, which is a trade name or a mark used in commerce, has been noted in this application. The term should be accompanied by the generic terminology; furthermore the term should be capitalized wherever it appears or, where appropriate, include a proper symbol indicating use in commerce such as ™, SM , or ® following the term.
Although the use of trade names and marks used in commerce (i.e., trademarks, service marks, certification marks, and collective marks) are permissible in patent applications, the proprietary nature of the marks should be respected and every effort made to prevent their use in any manner which might adversely affect their validity as commercial marks.
Additionally, the use of the abbreviation in the claims as “EP tube” should be replaced with the generic terminology. Appropriate correction is required.
Claims Summary
Claim 5 is directed to a method for detecting immune capture molecules which are complete HBV virus particles. The method comprises:
Antibody-magnetic bead coupling, wherein the antibody is a PreS1 antibody;
HBV virus particle capture; and
Real-time fluorescence qPCR
Claim 5 outlines the steps of the HBV particle capture process, comprising magnetic separation to discard a supernatant of the antibody-coupled magnetic bead preservation solution, washing, mixing with a diluted cell supernatant or serum of an HBV patient, wherein the antibody-coupled magnetic beads capture the HBV particles in the diluted patient sample. More details are outlined in claim 5. Claim 6 outlines the steps for antibody-magnetic bead coupling, including mixing the following in a buffer to activate the beads: carboxy magnetic beads, and equal amounts of an NHS solution and an EDC. Then, mixing and reacting the activated beads with an antibody to be coupled in a coupling buffer, thus obtaining an antibody-magnetic bead coupling reaction product. More detailed steps are outlined in claim 6. Claim 8 outlines the steps of the RT-qPCR.
Claim Objections
Claims 5, 6 and 8 are objected to because of the following informalities:
The term “EP tube” should be replaced with generic terminology. (See the objection to the specification above for the recitation of “Eppendorf”.)
Appropriate correction is required.
Claim Rejections - 35 USC § 112
The following is a quotation of the first paragraph of 35 U.S.C. 112(a):
(a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention.
The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112:
The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention.
Claim 8 is rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. This is a new matter rejection.
Claim 8 recites “a PCR reaction solution comprising primers, probes, dNTPs and DNA polymerase”. This limitation is not disclosed in the specification as originally filed. In the remarks filed August 24, 2026, Applicant asserts that the essential components of the PCR reaction mixture are standard components known in the art for rt-PCR.
In response, what is considered “standard” is relative. The specification does not disclose the PCR reagents such that they can be claimed by individual components (i.e., primers, probes, dNTPs and DNA polymerase). It is suggested to remove the individual components from the phrase (e.g., “placing PCR reagents at room temperature”).
Conclusion
No claim is allowed.
Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to Stacy B. Chen whose telephone number is 571-272-0896. The examiner can normally be reached on M-F (7:00-4:30). If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Thomas Visone, can be reached on 571-270-0684. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
/STACY B CHEN/Primary Examiner, Art Unit 1672